201 related articles for article (PubMed ID: 15847658)
1. Oxaliplatin-induced immune pancytopenia.
Taleghani BM; Meyer O; Fontana S; Ahrens N; Novak U; Borner MM; Salama A
Transfusion; 2005 May; 45(5):704-8. PubMed ID: 15847658
[TBL] [Abstract][Full Text] [Related]
2. Immune-mediated pancytopenia induced by oxaliplatin: a case report.
Fontão-Wendel R; Hoff PM; Lazar A; Freitas D; Novis Y; Patah P; Tsujita M; Balthazar A; Pierroti M; Wendel S
Transfusion; 2010 Jul; 50(7):1453-9. PubMed ID: 20210930
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?
James E; Podoltsev N; Salehi E; Curtis BR; Saif MW
Clin Colorectal Cancer; 2009 Oct; 8(4):220-4. PubMed ID: 19822513
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-induced immune mediated thrombocytopenia.
Beg MS; Komrokji RS; Ahmed K; Safa MM
Cancer Chemother Pharmacol; 2008 Oct; 62(5):925-7. PubMed ID: 18204841
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
Cobo F; De Celis G; Pereira A; Latorre X; Pujadas J; Albiol S
Anticancer Drugs; 2007 Sep; 18(8):973-6. PubMed ID: 17667605
[TBL] [Abstract][Full Text] [Related]
6. Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug-induced nonimmunologic protein adsorption.
Arndt P; Garratty G; Isaak E; Bolger M; Lu Q
Transfusion; 2009 Apr; 49(4):711-8. PubMed ID: 19192254
[TBL] [Abstract][Full Text] [Related]
7. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report.
Dahabreh I; Tsoutsos G; Tseligas D; Janinis D
BMC Clin Pharmacol; 2006 Sep; 6():5. PubMed ID: 16968538
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis.
Koutras AK; Makatsoris T; Paliogianni F; Kopsida G; Onyenadum A; Gogos CA; Mouzaki A; Kalofonos HP
Oncology; 2004; 67(2):179-82. PubMed ID: 15539924
[TBL] [Abstract][Full Text] [Related]
9. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells.
Grossjohann B; Eichler P; Greinacher A; Santoso S; Kroll H
Transfusion; 2004 Jul; 44(7):1033-40. PubMed ID: 15225244
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
12. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K
J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322
[TBL] [Abstract][Full Text] [Related]
13. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia.
Curtis SA; Curtis BR; Lee AI; Hendrickson JE; Lacy J; Podoltsev NA
Hematology; 2018 Aug; 23(7):429-432. PubMed ID: 29281948
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
15. An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Chen VM; Thrift KM; Morel-Kopp MC; Jackson D; Ward CM; Flower RL
Transfusion; 2004 Jun; 44(6):838-43. PubMed ID: 15157248
[TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity reactions to oxaliplatin in two asian patients.
Ng CV
Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin hypersensitivity: case report and successful repeat desensitization.
Edmondson DA; Gruling BJ; Urmanski AM; Wong SJ; Levy MB
Am J Ther; 2007; 14(1):116-8. PubMed ID: 17303980
[TBL] [Abstract][Full Text] [Related]
18. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
[TBL] [Abstract][Full Text] [Related]
20. Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
Wenzel C; Urbauer E; Schwarz C; Funk G; Oehler L; Kornek GV; Scheithauer W
Anticancer Drugs; 2006 Aug; 17(7):865-8. PubMed ID: 16926637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
